PMID: 6988267Jan 1, 1980Paper

Effect of insulin treatment on prostacyclin in experimental diabetes

Diabetologia
H E HarrisonM Johnson

Abstract

Diabetic patients have a high susceptibility to microvascular complications, atherosclerosis and thrombosis. Platelet hyperreactivity possibly related to an imbalance in arachidonic acid metabolism may be involved. Aortic rings or renal cortex produced a potent inhibitor of platelet aggregation, identified as prostacyclin (PGI2). Release of PGI2 by tissues from streptozotocin -- diabetic rats (aorta: 0.07 +/ 0.1 ng/mg wet weight; renal cortex 0.004 +/- 0.001 ng/mg wet weight) was significantly depressed when compared with controls (aorta: 0.26 +/- 0.07 ng/mg wet weight; renal cortex: 0.009 +/- 0.001 ng/mg wet weight). Treatment of diabetic animals with insulin for 8 days restored PGI2 production to normal. The finding that PGI2 is depressed in the aorta and in the kidney, tissues which develop angiopathy, and that this is normalised by insulin, suggests that impaired PGI2 production, perhaps associated with platelet hyperreactivity may play a role in the vascular complications of diabetes.

References

Feb 10, 1979·Lancet·M JohnsonJ B Elder
Jul 24, 1978·Life Sciences·H E HarrisonM Johnson
Jun 1, 1978·Pharmacological Research Communications·A SzczeklikJ Mruk
May 1, 1978·Archives of Ophthalmology·S WaltmanB Becker
Dec 15, 1977·The New England Journal of Medicine·P V HalushkaJ A Colwell
Aug 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·M HambergB Samuelsson
Apr 1, 1974·Proceedings of the National Academy of Sciences of the United States of America·R RossL Harker
Mar 1, 1973·Proceedings of the National Academy of Sciences of the United States of America·M Hamberg, B Samuelsson

Citations

Dec 15, 1985·Biochemical Pharmacology·D L Clark, S F Queener
Oct 14, 1983·European Journal of Pharmacology·S FunakawaY Tochino
Jan 14, 1992·European Journal of Pharmacology·H MasumuraY Abe
Feb 16, 1987·Life Sciences·I WakabayashiK Nagai
Jan 1, 1981·Prostaglandins·A Dembińska-KiećT Zelazny
Mar 1, 1983·Prostaglandins·Y C Kim, R G Brodows
Jan 1, 1985·Pharmacology & Therapeutics·A Kahán
Jan 1, 1981·Progress in Lipid Research·C N HensbyC T Dollery
Apr 7, 1998·Medicina clínica·J Ybarra, J C López-Talavera
Sep 1, 1987·The Proceedings of the Nutrition Society·J Betteridge
Jan 1, 1992·Clinical and Experimental Pharmacology & Physiology·W C HodgsonR G King
Feb 1, 1983·The British Journal of Ophthalmology·C R James, E Cotlier
Jan 1, 1983·Upsala Journal of Medical Sciences·U ErikssonT Tuvemo
Feb 1, 1986·Kidney International·P K JensenH H Parving
Apr 1, 1995·Prostaglandins, Leukotrienes, and Essential Fatty Acids·K Watanabe, E A Jaffe
Oct 1, 1993·Prostaglandins, Leukotrienes, and Essential Fatty Acids·S Hyslop, G De Nucci
Mar 1, 1984·Progress in Cardiovascular Diseases·N B Ruderman, C Haudenschild
Feb 1, 1983·Metabolism: Clinical and Experimental·P J VoisinP Drouin
May 1, 1990·Prostaglandins, Leukotrienes, and Essential Fatty Acids·T Mourits-AndersenJ Ditzel
Dec 1, 1980·Thrombosis Research·K A JørgensenJ Dyerberg
Oct 1, 1981·Thrombosis Research·H TakedaH Uzawa
Mar 1, 1981·The American Journal of Medicine·S M MauerD M Brown
Jan 1, 1985·Acta paediatrica Scandinavica·U Ewald, T Tuvemo
May 1, 1987·Clinical and Experimental Pharmacology & Physiology·A L BouraR G King
Nov 1, 1986·British Journal of Pharmacology·A L BouraR G King
Feb 1, 1982·Prostaglandins, Leukotrienes, and Medicine·C W KarpenR V Panganamala
Jul 27, 2001·Diabetes Care·A I VinikG L Pittenger
Nov 30, 1983·The American Journal of Medicine·J A ColwellP V Halushka
Jun 9, 2017·Clinical Science·Erik WesteinAnna C Calkin
Oct 3, 2018·International Journal of Molecular Sciences·Albino CarrizzoCarmine Vecchione
Nov 24, 1999·The American Journal of Physiology·A C PfluegerF G Knox
Oct 1, 1985·The American Journal of Physiology·T O MyersM E Gerritsen

Related Concepts

Abdominal Aorta Structure
Blood Glucose
Streptozotocin Diabetes
Novolin
Structure of Cortex of Kidney
Platelet Aggregation
Prostaglandins
Flolan

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Lipidomics & Rhinovirus Infection

Lipidomics can be used to examine the lipid species involved with pathogenic conditions, such as viral associated inflammation. Discovered the latest research on Lipidomics & Rhinovirus Infection.

Alzheimer's Disease: MS4A

Variants within the membrane-spanning 4-domains subfamily A (MS4A) gene cluster have recently been implicated in Alzheimer's disease in genome-wide association studies. Here is the latest research on Alzheimer's disease and MS4A.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Torsion Dystonia

Torsion dystonia is a movement disorder characterized by loss of control of voluntary movements appearing as sustained muscle contractions and/or abnormal postures. Here is the latest research.

Generating Insulin-Secreting Cells

Reprogramming cells or using induced pluripotent stem cells to generate insulin-secreting cells has significant therapeutic implications for diabetics. Here is the latest research on generation of insulin-secreting cells.

Central Pontine Myelinolysis

Central Pontine Myelinolysis is a neurologic disorder caused most frequently by rapid correction of hyponatremia and is characterized by demyelination that affects the central portion of the base of the pons. Here is the latest research on this disease.

Epigenome Editing

Epigenome editing is the directed modification of epigenetic marks on chromatin at specified loci. This tool has many applications in research as well as in the clinic. Find the latest research on epigenome editing here.